ArticleBMC cardiovascular disorders2026
Circulating angiopoietin-2 and TEK receptor tyrosine kinase-2 protein provide prognostic value in patients with acute myocardial infarction.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAcute myocardial infarction (AMI) is an acute heart disease that can result in high rates of disability and mortality. Biomarkers can reflect the pathophysiological progress of AMI, such as myocardial ischemia injury, ventricular remodelling and oxidative stress, and provide advantages in the prognostic evaluation of AMI. Finding novel biomarkers can help improve the risk stratification of AMI.
methodA total of 180 patients who were diagnosed with AMI in the Department of Cardiovascular Medicine of Hunan Provincial People's Hospital from July 2020 to March 2021 were included in this study. Baseline circulating ANGPT-2 and TIE-2 levels were measured, and patients underwent a regular follow-up to record the occurrence of major adverse cardiovascular events (MACE) after discharge.
resultsDuring the entire follow-up period with an average of 444 (356-586) days, 55 patients developed MACE. Multivariate Cox regression analysis revealed that ANGPT-2 (HR: 2.400; 95% CI: 1.380-4.523; P = 0.002) and TIE-2 (HR: 2.004; 95% CI: 1.127-3.562; P = 0.018) were independent predictors of MACE in patients with AMI. The area under the curve (AUC) of circulating ANGPT-2 for predicting MACE was 0.756 (95% CI: 0.682-0.785; P < 0.001), and the AUC of circulating TIE-2 for predicting MACE was 0.664 (95% CI: 0.572-0.755; P < 0.001).The Kaplan-Meier survival curve revealed that patients with an ANGPT-2 level ≥ 1.896 ng/mL had a greater risk of MACE than those with an ANGPT-2 level < 1.896 ng/mL (HR = 3.189; 95% CI: 1.856-5.481; P < 0.001), and patients with a TIE-2 level ≥ 21.886 ng/mL had a greater risk of MACE than those with a TIE-2 level < 21.886 ng/mL (HR = 2.912; 95% CI: 1.681-5.042; P < 0.001).
conclusionANGPT-2 and TIE-2 are significantly correlated with the prognosis of AMI, which suggests that they might be potential biomarkers for predicting prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.